Mylan's Agreement With Medicaid On Rebates For EpiPens Still Leaves A Key Question

One Wall Street analyst tells CNBC that a key for determining Medicaid's savings with the rebate will be a timing factor that was not disclosed when the agreement was announced. Also, some New York officials are coming under scrutiny for lax reporting on abuse of disabled Medicaid recipients.

CNBC: Mylan's Grace Period For EpiPen Rebates Could Cost Medicaid Up To $120 Million

The nearly six-month-long grace period drugmaker Mylan received before it has to pay full rebates for sales of its anti-allergy device could end up costing Medicaid tens of millions of dollars, an analyst said Tuesday. Or it could end up costing Medicaid not much at all. Because neither the federal government nor Mylan will explain what's going on with that grace period, it is not clear how much, or how little, Medicaid will end up being out of under the deal. (Mangan, 10/11)

The Associated Press: NY Agency Has No Record Of Required Referrals Of Abuse Cases

New York's oversight agency for the disabled has no record of forwarding abuse or neglect reports to the state Medicaid inspector general, a legally required step that's a key part of cracking down on problem facilities. Such reports are vital to protecting the more than 120,000 disabled people in state care because the inspector general's office has the power to cut off Medicaid funding to troubled facilities to force them to change their ways. (Virtanen, 10/12)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics